Pomalidomide

Catalog No.S1567

Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs.

Price Stock Quantity  
USD 91 In stock
USD 70 In stock
USD 120 In stock
USD 370 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Pomalidomide Chemical Structure

Pomalidomide Chemical Structure
Molecular Weight: 273.24

Validation & Quality Control

2 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Pomalidomide is available in the following compound libraries:

TNF-alpha Inhibitors with Unique Features

  • Most Potent TNF-alpha Inhibitor

    QNZ (EVP4593) TNF-α production, IC50=7 nM.

  • FDA-approved TNF-alpha Inhibitor

    Lenalidomide (CC-5013) Approved by FDA for myelodysplastic syndromes (MDS).

  • Newest TNF-alpha Inhibitor

    Necrostatin-1 Specific RIP1 inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM.

  • Classic TNF-alpha Inhibitor

    Thalidomide A sedative drug, immunomodulatory agent and also is investigated for treating symptoms of many cancers.

Product Information

  • Compare TNF-alpha Inhibitors
    Compare TNF-alpha Products
  • Research Area

Product Description

Biological Activity

Description Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs.
Targets TNF-α [1]
(PBMCs)
IC50 13 nM
In vitro Pomalidomide inhibits lipopolysaccharide (LPS) stimulated TNF-alpha release in human PBMC and in human whole blood with IC50 values of 13 nM and 25 nM, respectively. [1] Pomalidomide inhibits the growth of T regulatory cells which is stimulated by IL-2 with an IC50 of ~1 μM. [2] Treatment with Pomalidomide (6.4 nM-10 μM) increases the production of IL-2 in human peripheral blood T cells, and is slightly more potent in the CD4+ subset than in the CD8+ subset. Pomalidomide is significantly more potent than CC-5013 at elevating IL-2, IL-5, and IL-10 levels, but only slightly more potent than CC-5013 at elevating IFN-γ levels. Pomalidomide enhances SEE and Raji cells induced AP-1 transcriptional activity in Jurkat cells in a dose-dependent manner, with a maximal enhancement of 4-fold at 1 μM. [3] Exposure of Raji cells to various concentrations of Pomalidomide (2.5-40 μg/mL) for 48 hours leads to a significant decrease in cell proliferation and DNA synthesis. There is a reduction of ~40% compared to vehicle-treated controls. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
MOLP-8MY\DfZRwfG:6aXPpeJkhSXO|YYm=Mk[1NVAh|ryPM1LTNVI1KGh?MkXzdI91\W62bImgZZVodWWwdIOg[Ilz\WO2IHHu[EBqdmSrcnXjeEBOVSClZXzsJItqdGyrbnegZpkhW0GUNVrL[lBNOjZ|M{iyO|M>
J-CD38MmjIR5l1d3SxeHnjbZR6KEG|c3H5MnflNVAh|ryPMVmyOEBpMWXwc5RmdnSueTDheYdu\W62czDkbZJm[3RiYX7kJIlv\Gm{ZXP0JG1OKGOnbHygb4ltdGmwZzDifUBUSVJ?NY\xWGxLOjZ|M{iyO|M>
R-CD38NVzi[oRDS3m2b4TvfIlkcXS7IFHzd4F6M4Tz[FExKM7:TR?=NGfjdWszPCCqMofTdI91\W62bImgZZVodWWwdIOg[Ilz\WO2IHHu[EBqdmSrcnXjeEBOVSClZXzsJItqdGyrbnegZpkhW0GUNWXuVW1VOjZ|M{iyO|M>
BC-3MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MW[zPU0yOjVyIH7NM{fBXVUh\A>?NXPKbFdFTE2VT9MgM4W5bGlEPTB;MUC3JI5ONCCrbnjpZol1eyClZXzsJGlEPTB;MUC3JI5ONCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?MkfJNlYyOTl7M{m=
BCBL-1MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWKzPU0yOjVyIH7NMUW1JIQ>NYiyTI1TTE2VT9MgMn61TWM2OD15NDDuUUwhcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=MlTZNlYyOTl7M{m=
JSC-1NXPBfGl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NULQTHdbOzlvMUK1NEBvVQ>?NEC0PVY2KGR?MYHEUXNQyqB?NW\ye2trUUN3ME2zOEBvVSxiaX7obYJqfHNiY3XscEB3cWGkaXzpeJkh\G:|ZTDk[ZBmdmSnboTsfS=>NEnCVJEzPjFzOUmzPS=>
VG-1NW\jfm1KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlTsN|kuOTJ3MDDuUS=>NGnyVo02KGR?M2jCeWROW00EoB?=MWLJR|UxRTFyMTDuUUwhcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=M3ztdlI3OTF7OUO5
UMPEL-1MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXi5NY1[OzlvMUK1NEBvVQ>?M4H4[|Uh\A>?M{nJ[GROW00EoB?=M1nMTWlEPTB;M{Kgcm0tKGmwaHnibZR{KGOnbHygeoli[mmuaYT5JIRwe2ViZHXw[Y5l\W62bIm=NETFNowzPjFzOUmzPS=>
UMPEL-3NXzRfVU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4W2NFM6NTF{NUCgcm0>MX:1JIQ>NV;VNHoxTE2VT9MgMofwTWM2OD1zMUGgcm0tKGmwaHnibZR{KGOnbHygeoli[mmuaYT5JIRwe2ViZHXw[Y5l\W62bIm=MXeyOlEyQTl|OR?=
BC-1MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2jwRVM6NTF{NUCgcm0>NWHpR4NNPSCmM1vaR2ROW00EoB?=Mlf1TWM2OD15NESgcm0tKGmwaHnibZR{KGOnbHygeoli[mmuaYT5JIRwe2ViZHXw[Y5l\W62bIm=MX[yOlEyQTl|OR?=
BCP-1NV\jXnZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3PwelM6NTF{NUCgcm0>NYjsfoNIPSCmNI\NdmdFVVORwrC=NFvsfnVKSzVyPUO5OkBvVSxiaX7obYJqfHNiY3XscEB3cWGkaXzpeJkh\G:|ZTDk[ZBmdmSnboTsfS=>M1\iRVI3OTF7OUO5
APK-1MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NG\JTIw{QS1zMkWwJI5OMmLFOUBlMnXSSG1UV8LiNWHTOXRuUUN3ME2yNlYhdk1uIHnubIljcXS|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk>M1nxNVI3OTF7OUO5
RPMI8226 MljoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVPnTI1NOC5yMT21NEDPxE1?NUjIVZRsPDhiaB?=NV;zNHJ4TE2VT9MgNXyyZW86UUN3ME24JO69VQ>?MlLWNlYxQTd6N{K=
OPM2 NYXLOJNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3zDflAvODFvNUCg{txONHjZWmQ1QCCqNHHNVmxFVVORwrC=MUDJR|UxRTFyIN88US=>M4\Vc|I3ODl5OEey
RPMI8226 NEfvPG5HfW6ldHnvckBCe3OjeR?=NHeydmEyOCEQvF2=MlW3OFghcA>?NYTlNYJWTE2VT9MgMWXzeJJmdme2aHXud{BkgXSxcHzhd41q[y2wdXPs[YFzKHOqdYT0cIlv\yCxZjDtWG9TKGGwZDDwMY1VV1JicILveIVqdg>?NWTK[3hlOjZyOUe4O|I>
OPM2 M3vobWZ2dmO2aX;uJGF{e2G7MV2xNEDPxE1?MnrxOFghcA>?NGTxVodFVVORwrC=MmTqd5Rz\W6pdHjlcpMh[3m2b4DsZZNucWNvboXjcIVieiC|aIX0eIxqdmdib3[gcXRQWiCjbnSgdE1uXE:UIIDyc5RmcW5?Ml;lNlYxQTd6N{K=
RPMI8226NFXKOnBHfW6ldHnvckBCe3OjeR?=NFe5co4xNjFvMUCg{txOMVO0JIg>Ml;0SG1UV8LiMUDpcoNz\WG|ZYOgWmVITiCvUl7BJIV5eHKnc4Ppc44>NX:5PIFzOjVyNUO5PVA>
SH-SY5Y Mk\RRZBweHSxc3nzJGF{e2G7MW[yOeKh|rypL33MM1rwWFHDqGh?MV;jZZV{\XNic4TheIl{fGmlYXzsfUB{cWewaX\pZ4FvfCC{ZXT1Z5Rqd25iaX6gZo91cCCFUF[tJIFv\CCFUF[rR20ucW6mdXPl[EBieG:ydH;zbZPDqA>?MoG1NlQ6PzV{N{[=
JJN3MkD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnK1NE4yNTFyMDFOwG0>NGjObXQ4OiCqMVPEUXNQMWDpcohq[mm2czDj[YxtKGe{b4f0bEB{dGmpaITsfS=>NX7xfpJZOjNzN{izO|g>
XG-1NVvISJVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3vuU|AvOS1zMECg{txONX;MbYhlPzJiaB?=MXrEUXNQMVjpcohq[mm2czDj[YxtKGe{b4f0bC=>NG\VS2ozOzF5OEO3PC=>
CD138+ NUHiXmx3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{j0[FAvOS1zMECg{txONUHZWFVHPzJiaB?=NIjOVZdFVVORMnXWbY5pcWKrdIOgZ4VtdCCpcn;3eIg>NIjTfIEzOzF5OEO3PC=>
XG-1NF7HW4FHfW6ldHnvckBCe3OjeR?=NWnIN4RuOi9zMECg{txOM3rlPFI1KGh?MUTEUXNQMYTpcohq[mm2czDDR2w{N02LUD2x{tEhdVKQQTDlfJBz\XO|aX;uNEXvXW0zOzF5OEO3PC=>
U266M3vFU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFvVUVcxNjBzLUGwJO69VQ>?NVvKfph3PDkkgJnoMUTEUXNQNFuxS49qdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6MlP0NlI2PTJyMEi=
CRBN60MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWmwMlAyNTFyIN88US=>Mmf5OFjjiImqNUf2SmpETE2VTx?=NGDVNmVqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6M3XGTlIzPTV{MEC4
CRNB75MnHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmnlNE4xOS1zMDFOwG0>Mnq0OFjjiImqNWHkR2JiTE2VTx?=NV3iPHF5cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>?NV\RN5I1OjJ3NUKwNFg>
MM.1SMlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NW\QXXJxOC5yMT2xNEDPxE1?NHi4fGk1QOLCiXi=NH35Ro1FVVORNV\xUFdie2mpbnnmbYNidnSueTDpcohq[mm2czDwdo9tcW[ncnH0bY9vKGG2IHPvcoNmdnS{YYTpc45{KGG|IHzve{BieyByLkCx{txONXPUTZIzOjF|OEmzNlc>
OPM2M4jONmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlfyNE4xOS1zMDFOwG0>MVm0PQKBkWh?NF\3SoFFVVORM2DZ[JNq\26rZnnjZY51dHliaX7obYJqfHNicILvcIln\XKjdHnvckBifCClb37j[Y51emG2aX;ud{BieyCub4egZZMhOC5yMd88US=>NYDNc2JoOjF|OEmzNlc>
MM.1SNX[zbZpGTnWwY4Tpc44hSXO|YYm=NYTXN|JqOTBizszNMnzIO|IhcA>?NFLSc2NFVVORMn3Md4lodmmoaXPhcpRtgSCmZXPy[YF{\XNidHjlJJBzd3SnaX6gcIV3\Wxib3[gR{9GSlEQsjDpd49nd3Kvc9MgNYTNb5YxOjF|OEmzNlc>
H929MWfGeY5kfGmxbjDBd5NigQ>?Mke1NVAh|ryPM4LYUlczKGh?NEHrVItFVVORNFG3eWh{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczD0bIUheHKxdHXpckBt\X[nbDDv[kBEN0WEUN8yJIl{d2[xcn3zxsA>MV2yNVM5QTN{Nx?=
OPM2Ml64SpVv[3Srb36gRZN{[Xl?NV7PToh2OTBizszNMnzCO|IhcA>?NIPSWYFFVVORNVfuWWNQe2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgeIhmKHC{b4TlbY4hdGW4ZXygc4YhSy:HQmFOtkBqe2:ob4Ltd:KhNWXKV4N2OjF|OEmzNlc>
CT26MVPGeY5kfGmxbjDBd5NigQ>?MY[xM|ExKM7:TR?=NUHncJM3OjRiaB?=NF6xZ5dz\WS3Y3XzJJRp\SCwdX3i[ZJ{KG:oIHzpeoUh[2:ub37p[ZPDqA>?NXTyXop[OTl4M{i5O|c>

... Click to View More Cell Line Experimental Data

In vivo Pomalidomide enhances the antitumor effect of rituximab against B-cell lymphomas in severe combined immunodeficient mice. Administration of Pomalidomide in combination with rituximab, gives the mice a median survival period of 74 days compared with 58 days of CC5013/rituximab treatment and 45 days of rituximab nonotherapy. The synergistic effect of Pomalidomide and rituximab can be completely abrogated by depletion of NK cells, supporting the proposal that NK cell expansion is one mechanism by which Pomalidomide may augment rituximab antitumor activity. [4]
Features A derivative of thalidomide and up to 10,000 times more potent than thalidomide.

Protocol(Only for Reference)

Kinase Assay: [1]

Inhibition of TNF-α synthesis TNF-α inhibitory activity is measured in lipopolysacharide (LPS) stimulated PBMC. Pomalidomide is added to human PBMCs 1 hour prior to the addition of LPS (1 μg/mL) and incubation continued for an additional 18-20 hours. Supernatants are then harvested, and the concentration of TNF-α in the supernatants is determined by ELISA. The concentration of Pomalidomide that inhibits TNF- production by 50% (IC50) is calculated by nonlinear regression analysis. The human whole blood TNF- inhibition assay is run in a similar fashion to the PBMC assay except that heparinized fresh human whole blood is plated directly into microtiter plates.

Cell Assay: [4]

Cell lines Raji, SU-DHL-4 and SU-DHL-10 cell lines
Concentrations Dissolved in DMSO, final concentrations 2.5-40 μg/mL
Incubation Time 24 or 48 hours
Method For assessment of cell apoptosis, Lymphoma cell lines are exposed to Pomalidomide (5 μg/mL) for 24 hours or 48 hours. The cells are stained with FITC-labeled Annexin V and propidium iodine. Cell apoptosis is analyzed by multicolor flow cytometric analysis using a fluorescence-activated cell sorter/FACStar Plus flow cytometer. Cells are scored as apoptotic if they are Annexin V–positive and propidium iodine–negative/positive (early and late apoptosis, respectively). For determination of cell proliferation, the Lymphoma cell lines are exposed to Pomalidomide (2.5, 5, 10, 20, and 40 μg/mL) for 24 hours or 48 hours. 1 μCi per well (96-well plate) of [3H]-thymidine is added and cells are incubated for another 18 hours. Cells are then harvested using the Harvest system into the 96-well glass filters and [3H]-thymidine uptake is measured using an automated scintillation counter.

Animal Study: [4]

Animal Models Disseminated lymphoma-bearing SCID mice
Formulation Dissolved in DMSO to make a 10 mg/mL stock solution and diluted to a final concentration of 1 mg/mL in sterile 0.9% normal saline.
Dosages 0.5 mg/kg
Administration Injection i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Muller GW, et al. Bioorg Med Chem Lett, 1999, 9(11), 1625-1630.

[2] Galustian C, et al. Cancer Immunol Immunother, 2009, 58(7), 1033-1045.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02807454 Recruiting Multiple Myeloma Celgene Corporation July 2016 Phase 1|Phase 2
NCT02718833 Recruiting Multiple Myeloma Massachusetts General Hospital|Celgene|Bristol-Myers Squibb June 2016 Phase 2
NCT02569320 Recruiting Recurrent Plasma Cell Myeloma Yvonne Efebera|Celgene|Ohio State University Comprehensiv  ...more Yvonne Efebera|Celgene|Ohio State University Comprehensive Cancer Center May 2016 Phase 1
NCT02726581 Recruiting Multiple Myeloma Bristol-Myers Squibb|AbbVie April 2016 Phase 3
NCT02406222 Recruiting Multiple Myeloma University of Leeds|Myeloma UK|Celgene March 2016 Phase 2

view more

Chemical Information

Download Pomalidomide SDF
Molecular Weight (MW) 273.24
Formula

C13H11N3O4

CAS No. 19171-19-8
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms CC-4047
Solubility (25°C) * In vitro DMSO 55 mg/mL (201.28 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80 15 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related TNF-alpha Products

  • MI-773 (SAR405838)

    MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.

  • A-1210477

    A-1210477 is a potent and selective MCL-1 inhibitor with Ki and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.

  • Thalidomide

    Thalidomide was introduced as a sedative drug, immunomodulatory agent and also is investigated for treating symptoms of many cancers. Thalidomide inhibits an E3 ubiquitin ligase, which is a CRBN-DDB1-Cul4A complex.

  • Necrostatin-1

    Necrostatin-1 is a specific RIP1 inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM in 293T cells.

    Features:A powerful tool for characterizing the role of necroptosis with characterized primary target.

  • Z-VAD-FMK

    Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

    Features:A key compound for apoptosis studies.

  • ABT-263 (Navitoclax)

    ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

  • Venetoclax (ABT-199, GDC-0199)

    Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

    Features:Re-engineered version of ABT-263 (Navitoclax).

  • ABT-737

    ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

Recently Viewed Items

Tags: buy Pomalidomide | Pomalidomide ic50 | Pomalidomide price | Pomalidomide cost | Pomalidomide solubility dmso | Pomalidomide purchase | Pomalidomide manufacturer | Pomalidomide research buy | Pomalidomide order | Pomalidomide mouse | Pomalidomide chemical structure | Pomalidomide mw | Pomalidomide molecular weight | Pomalidomide datasheet | Pomalidomide supplier | Pomalidomide in vitro | Pomalidomide cell line | Pomalidomide concentration | Pomalidomide nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us